Novavax NVAX | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Novavax NVAX

An SI Board Since March 2002

Posts	SubjectMarks	Bans	Symbol
166	18	0	NVAX

Emcee: Jack Hartmann	Type: Moderated

Introduction Market Data Compact

Novavax is rising $1.21, or 11.5 percent, to $11.70, after the Los Angeles biopharmaceutical firm reported positive results of a phase III trial of Estrasorb, its experimental treatment for vasomotor symptoms, or hot flashes, in postmenopausal women. The company said that patients using Estrasorb in the randomized, double-blind trial experienced an 85 percent reduction in the total number of hot flashes during the course of the trial. Novavax also said that about half of the patients reported complete cessation of hot flashes during a 7-day period by week 10 of the treatment. Fewer than 10 percent of the patients in the placebo group noticed a similar improvement.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
166	So much potential. And so much pain for longs. Really a shame it's come t	Paul Senior	-	2/28/2023
165	Say goodbye, adios.. Disastrous earning report. Gone unless figure out major dil	Jatin Kadakia	-	2/28/2023
164	finance.yahoo.com Correct link.	Jatin Kadakia	-	1/14/2023
163	finance.yahoo.com May be new incoming ceo can right the ship. They need to exec	Jatin Kadakia	-	1/14/2023
162	So Yahoo has a 61.5 yearly target on this. I've no idea how to value this c	epicure	-	1/5/2023
161	No argument from me about their problems with execution. I just wonder what the	epicure	-	12/16/2022
160	As Paul mentioned, they are pathetic in execution. Too much dilution and reverse	Jatin Kadakia	-	12/16/2022
159	At some point it is a buy. There's value there. I've no idea how much,	epicure	-	12/16/2022
158	Poor NVAX. I've been out of it for a while, but still... poor me. One of	Paul Senior	-	12/15/2022
157	Yikes. Oh woe is me. I'll cut back substantially. Add back if/when I se	Paul Senior	-	8/8/2022
156	Getting hammered after hours. Now they can't sell enough vax.	Jatin Kadakia	-	8/8/2022
155	CDC clears Novavax Covid-19 vaccine for adults, says shots will be available i	Glenn Petersen	-	7/20/2022
154	Oops. Stock taking a huge drop. Sell on the news I understand. But a 24% fall	Paul Senior	-	7/14/2022
153	Thanks for the news! Now if only the stock could move up.	Paul Senior	-	7/13/2022
152	FDA granted EUA today. Next step: CDC on July 19th: theguardian.com	recycled_electron	-	7/13/2022
151	Possible FDA approval (for primary vaccination series in the US) tomorrow (July	recycled_electron	-	7/12/2022
150	Trading after hours around 55 in the post market.. for now.	Ron	1	6/7/2022
149	Finally!!!! FDA advisory panel recommends approval of a 4th US vaccine (Novavax)	recycled_electron	-	6/7/2022
148	Ok, thanks.	Paul Senior	-	6/7/2022
147	You can hear the FDA deliberations live, if interested: youtube.com Novavax Sta	recycled_electron	-	6/7/2022
146	As I understand it, it is a recommendation that's happening or not. Then th	Paul Senior	1	6/7/2022
145	Stock is halted for now. We'll see what the proceedings bring. Will be ver	Ron	-	6/7/2022
144	Novavax faces high-stakes FDA review this week that will decide the fate of its	Glenn Petersen	1	6/6/2022
143	Yet again I add to my most losing position. (buying more today) If the game is	Paul Senior	1	6/3/2022
142	Meanwhile, dark storm clouds gather before the June 7th meeting: NVAX NOVAVAX I	recycled_electron	-	6/3/2022

Go to reply# or date (mm/dd/yy):